• Boehringer Ingelheim lands option on cystic fibrosis gene therapy fiercebiotech
    August 07, 2018
    Boehringer Ingelheim has secured the option to license a cystic fibrosis gene therapy. The agreement will see Boehringer work with British academics and Oxford BioMedica (OXB) to develop an inhaled, lentiviral vector-based gene therapy treatment for cysti
PharmaSources Customer Service